ESC 2022: BMS, J&J's secondary stroke med falls short
in phase 2, but companies see enough potential to push forward
A new interim
analysis of Bristol Myers Squibb's anticoagulant milvexian as a treatment for
secondary strokes shows a mixed bag of data. The drug failed its primary
endpoint, but a reduction in stroke incidence among three dosing groups beat
the company's expectations.
No comments:
Post a Comment